Severe von Willebrand disease patient registry in the U.S.
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This registry collects health and bleeding information from people who have severe von Willebrand disease (a lifelong bleeding condition). Your data helps researchers understand the condition better and supports future studies that may lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of von Willebrand disease (from your doctor or your own confirmation).
- You meet severe criteria based on VWF lab results (often very low), or you have significant bleeding problems.
- You (or a legal representative) can give informed consent to join the registry.
- You live in the United States.
- You can follow study steps and share required information for data collection.
- You do not have acquired von Willebrand disease (a type caused by another condition, not lifelong VWD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This study looks at special cells from blood vessels (endothelial colony-forming cells) in people with von Willebrand disease (a bleeding disorder) or a related acquired condition. The goal is to better understand these conditions using blood donations.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
Hear when a new VWD - Von Willebrand's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.